Items where authors include "Rahman, P"

Article

McGonagle, D, McInnes, IB, Deodhar, A et al. (10 more authors) (2023) Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies. ACR Open Rheumatology, 5 (4). pp. 227-240. ISSN 2578-5745

Coates, LC, Tillett, W, D'Agostino, MA et al. (8 more authors) (2022) Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study. The Lancet Rheumatology, 4 (4). e262-e273. ISSN 2665-9913

Rahman, P, Mease, PJ, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (10 more authors) (2021) Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis Research and Therapy, 23 (1). 190. ISSN 1478-6354

McInnes, IB, Mease, PJ, Kivitz, AJ et al. (9 more authors) (2020) Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. The Lancet Rheumatology, 2 (4). e227-e235. ISSN 2665-9913

Brown, P, Tan, A-C, El-Esawi, MA et al. (1578 more authors) (2019) Large expert-curated database for benchmarking document similarity detection in biomedical literature search. Database - The Journal of Biological Databases and Curation.

Cortes, A, Maksymowych, WP, Wordsworth, BP et al. (16 more authors) (2015) Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. Annals of the Rheumatic Diseases, 74 (7). pp. 1387-1393. ISSN 0003-4967

Conference or Workshop Item

Rahman, P, Ritchlin, C, Mease, P et al. (10 more authors) (2022) Long-term Safety of Guselkumab in Patients With Active Psoriatic Arthritis: Pooled Results From 3 Randomized Clinical Trials Through Up to 2 Years. In: Open Access Canadian Rheumatology Association Annual Meeting, 02-05 Feb 2022, Online.

Kavanaugh, A, Liu, Y, Deodhar, A et al. (8 more authors) (2021) Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 DISCOVER Program. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Coates, L, Ritchlin, C, Gossec, L et al. (12 more authors) (2021) Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Rahman, P, Ritchlin, C, Mease, P et al. (11 more authors) (2021) Long-term Safety of Guselkumab (TREMFYA (R)) in Patients with Active Psoriatic Arthritis: Pooled Results from 3 Randomized Clinical Trials Through up to 2 Years. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Ritchlin, CT, Rahman, P, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (7 more authors) (2021) Safety of guselkumab in patients with psoriatic arthritis through 1 year: Pooled findings from DISCOVER-1 and DISCOVER-2 phase 3 trials. In: AAD VMX 2021, 23-25 Apr 2021, Virtual.

Kavanaugh, A, Liu, Y, Deodhar, A et al. (8 more authors) (2021) Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 Discover Program. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Coates, LC, Ritchlin, CT, Gossec, L et al. (12 more authors) (2021) Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as Assessed using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Rahman, P, Helliwell, P orcid.org/0000-0002-4155-9105, Deodhar, A et al. (6 more authors) (2021) In Phase-3 Trials Discover 1 & 2, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue after Adjustment for Clinical Response (ACR20). In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Ritchlin, CT, Rahman, P, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (13 more authors) (2021) Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis through 1 Year. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Coates, LC, Ritchlin, CT, Gossec, L et al. (12 more authors) (2021) Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Rahman, P, Ritchlin, C, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (12 more authors) (2021) Integrated Safety Results of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis through the Placebo-Controlled Periods. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Coates, L, Ritchlin, C, Gossec, L et al. (12 more authors) (2020) Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: ACR Convergence 2020, 05-09 Nov 2021, Virtual.

Rahman, P, Ritchlin, CT, Helliwell, P et al. (13 more authors) (2020) FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS. In: EULAR 2020, 03-06 Jun 2020, Online.

Helliwell, P, Rahman, P, Deodhar, A et al. (6 more authors) (2020) SAT0421 GUSELKUMAB DEMONSTRATED AN INDEPENDENT TREATMENT EFFECT ON FATIGUE AFTER ADJUSTMENT FOR CLINICAL RESPONSE (ACR20) IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM PHASE-3 TRIALS DISCOVER 1 & 2. In: EULAR 2020, 03-06 Jun 2020, Online.

Deodhar, A, Kirkham, B, Rahman, P et al. (6 more authors) (2020) P277 Assessment of disease activity using RAPID3 and evaluation of treatment effect of guselkumab in patients with PsA: results from a randomised placebo-controlled Phase 2 clinical trial. In: British Society for Rheumatology Annual Conference 2020, 20-22 Apr 2020, Cancelled.

Proceedings Paper

Gossec, L, Kirkham, B, Rahman, P et al. (4 more authors) (2018) Clinically Meaningful Improvement in Health-Related Quality of Life and the Association with Disease Activity in Psoriatic Arthritis after Treatment with Guselkumab: Results from a Randomized Placebo-Controlled Phase II Clinical Trial. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .

Genovese, M, Helliwell, P, Combe, B et al. (6 more authors) (2018) Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF inhibitors: 52-week Results from a Phase 3 Study. In: Journal of Rheumatology. 73rd Annual Meeting of The Canadian-Rheumatology-Association (CRA), 21-24 Feb 2018, Vancouver, Canada. Journal of Rheumatology Publishing Co., Ltd. , p. 996.